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Objective: to evaluate the association between Lp(a) lipoprotein levels, other serum lipids and the presence of lower limb
atherosclerotic occlusive disease.
Materials and methods: angiographic findings in 36 patients were related to serum Lp(a). Total cholesterol, triglycerides,
LDL-cholesterol, HDL-cholesterol and Lp(a) levels were compared with those of 73 age- and sex-matched healthy controls.
Results: atheromatous lesions were localised in the femoropopliteal (≈60%) and aortoiliac (≈40%) segments. The
number of stenosed arteries was [2 and the range of stenosis severity was between 40% and 100%. There was a
significant increase in serum Lp(a) (p=0.000001) and a decrease in serum HDL (p=0.000009) levels in patients
compared to controls. No difference was observed in total cholesterol, LDL-cholesterol or triglyceride. However, the ratio
of total cholesterol/HDL-cholesterol was significantly higher (p=0.005) in patients.
Conclusion: a dyslipidaemic serum profile, characterised by increased Lp(a) levels and decreased HDL-cholesterol levels,
is associated with atherosclerotic occlusive disease of the lower extremities.
Key Words: Lipoprotein (a) (Lp(a)); High density lipoprotein (HDL); Atherosclerotic occlusive disease; Peripheral vascular
disease (PVD).
Materials and MethodsIntroduction
SubjectsThe factors determining the distribution of athero-
sclerosis are not well defined but may relate to patterns
Thirty-six patients (29 males and seven females agedof dyslipidaemia.1,2 Peripheral vascular disease (PVD)
51–84 years) with a severe acute vascular occlusivehas usually been associated with an increase in tri-
episode affecting the lower extremities were studied.glycerides and a reduction in HDL plasma levels.3–5
Individuals with renal or hepatic dysfunction, andRecent evidence from several studies has emphasised
those taking corticosteroids or lipid-modifying med-the importance of recently described cardiovascular
ication, were excluded. Thirty-three of the patientsrisk factors such as lipoprotein (a) (Lp(a)) and lipid
underwent retrograde transcutaneous angiography10oxidation.1,3,6,7 Lp(a) is involved in lipid metabolism,
and three (one male and two females) underwentcoagulation and fibrinolysis, as well as the stimulation
intravenous digital subtraction angiography.3 None ofof vascular smooth-muscle cell proliferation.8 A posi-
the patients had had previous angiography or previoustive correlation has already been found between Lp(a)
vascular surgery. Twenty-seven of the patients (23serum levels and the degree of carotid atherosclerosis.9
males and four females) were being treated for diabetesThe situation with regard to lower extremity athero-
mellitus (glibenclamide or insulin). Approximatelysclerosis has not yet been investigated. The present
40% of the patients were hypertensive.study was undertaken to correlate the angiographic
A group of 73 healthy non-obese individuals (60findings in such patients with serum Lp(a) levels.
males and 13 females), aged 50–75 years, with no
family history of cardiovascular or peripheral artery
disease, served as controls. They were assessed clin-
ically and underwent duplex ultrasound examination.
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Table 1. Serum lipid, low-density lipoprotein (LDL) cholesterol,
high-density lipoprotein (HDL) cholesterol and lipoprotein(a)
(Lp(a)) levels of the studied individuals.
Patients Controls p
(n=36) (n=73)
Total cholesterol 190±67 212.5±44.5 NS
(mg/dl)
Triglycerides (mg/dl) 139±126 119±56 NS∗
LDL-cholesterol 131±49 140±43 NS
(mg/dl)
LDL-cholesterol 114±52 135±42 <0.05∗
corrected∗∗ (mg/dl)
HDL-cholesterol 31±11 49±13 0.000009
(mg/dl)
Total cholesterol: HDL 6.30±1.91 4.6±1.4 0.005
cholesterol ratio
Lp(a) (mg/dl) 54±64 16±21 0.000001
median (range) 28.57 (0.69–278) 7.5 (0.75–113)
Values are given as means±standard deviations.
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Fig. 1. Box and Whisker plot of Lp(a) serum levels in the studied∗∗Corrected for cholesterol in Lp(a). See Materials and Methods.
individuals. (I) Min–max; (Φ) 25–75%; (Φ) median value.
Lipoprotein analysis obtained through summation of the most severe
lesions seen in the obstructed vessels. Arterial score
Blood samples were taken prior to angiography, after and Lp(a) were correlated using Spearman’s rank cor-
an overnight fast (12 h). The serum was separated relation coefficient.
by centrifugation (1500 g for 15 min). HDL-cholesterol
was determined after precipitation of VLDL and LDL
by magnesium chloride and dextran sulphate. Serum
Resultscholesterol and triglycerides, as well as HDL-cho-
lesterol, were measured in a Cobas Mira Plus (Roche)
The distribution of Apo(a) or Lp(a) protein levelsautoanalyser. LDL-cholesterol was calculated ac-
among patients and controls was highly skewed (Fig.cording to Friedewald’s equation and corrected for
1) (Table 1). Considerable variation was reported ascholesterol in Lp(a).11
to the distribution of Lp(a) in a reference study ofSerum Apo(a) concentration was measured with
Lp(a) levels in the Greek population.12a two-site immunoradiometric assay (2-site IRMA)
Patients had significantly higher Lp(a) and sig-(Pharmacia Diagnostics AB, Uppsala, Sweden). This
nificantly lower HDL levels than controls. There wasmethod uses two monoclonal antibodies of human
no difference in the levels of total cholesterol, LDL-Apo(a) in excess. After hydrolysis and dilution, the
cholesterol or triglyceride serum between patients andserum samples were incubated with an excess of 25I by
controls. The values of LDL-cholesterol corrected forcentrifugation and their radioactivity was measured. A
cholesterol in Lp(a)11 are significantly lower in patientsstandard curve was made for each assay. All samples
than in controls as a result of the higher Lp(a) valueswere assayed in duplicate. The within-assay coefficient
in the patients. A significant increase in the ratioof variation was 5% (n=10); 1 U/l Apo(a) corresponds
of cholesterol/HDL-cholesterol was also observed inapproximately to 0.1 mg/dl of Lp(a) protein.
patients (p=0.005).
Angiographic scores are shown in Table 2. The level
of stenosis of the vessels concerns:Statistical analysis
1. The aortoiliac axis: aorta (A); common iliac, right–The data were analysed using the SPSS and Student’s left (Cl) (r) (l); external iliac, right–left (El) (r) (l).
t-test was used for normally distributed data and 2. Femoropopliteal axis: common femoral, right–leftthe Wilcoxon test for non-parametric data [Lp(a)]. (CF) (r) (l); superficial femoral (SF) (r) (l); popliteal,Whenever necessary, the data were transformed to right–left (P) (r) (l).natural logarithms before analysis. Determination of 3. Tibiopedal axis: anterior tibial (AT) (r) (l).artery lesion score was performed according to Dahlen
et al.11 An artery score for each patient (Table 1) was Only the site, not the severity, of the losses was assessed
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Table 2. Classification of the stenosis of vascular arterial stems (%) in angiography in the 33 patients who were subjected to retrograde
transcutaneous angiography in contrast to the Lp(a) serum levels.
Case numbers A∗ C.I. (r) C.I. (l) E.I. (r) E.I. (l) C.F. (r) C.F. (l) S.F. (r) S.F. (l) P (r) P (l) A.T. (r) A.T. (l) Lp(a)
1 90 100 41.9
2 80 50 79
3 100 60 8.56
4 40 20 30.54
5 80 7.93
6 100 100 100 7.12
7 80 100 100 100 3.41
8 85 100 100 29.6
9 95 90 133.76
10 60 100 100 95 100 100 100 140.91
11 80 70 8.36
12 100 100 100 100 15.8
13 85 75 9.62
14 80 80 100 172.3
15 80 60 114.9
16 65 100 50 100 26.26
17 40 60 80 60 61.71
18 100 26.96
19 50 40.3
20 70 40 97.73
21 60 80 75 109.49
22 80 100 8.56
23 DL DL DL 66.25
24 UCA 278.27
25 100 27.54
26 DL DL 80 DL DL DL 176.66
27 DL 18.45
28 100 3.89
29 95 100 9.51
30 80 100 114.51
31 85 90 0.7
32 UA 5.39
33 DL DL DL DL DL 0.69
The values of Lp(a) lipoprotein are expressed in mg/dl. DL=Diffuse lesions, UA=Ulceration of aorta, UCA=Ulceration and coiled aorta.
∗ For abbreviation see Results.
in the three patients who underwent intravenous di- in total cholesterol or LDL-cholesterol levels in patients
gital subtraction angiography (Table 2). No statistically with atherosclerotic occlusive disease of the lower
significant correlation was observed between angio- extremities. However, there was a significant decrease
graphic scores and Lp(a) levels. in HDL-cholesterol, resulting in an elevation of the
ratio of cholesterol/HDL-cholesterol in comparison to
the controls. More frequently, the disease was as-
sociated with an increase in triglycerides and with aDiscussion
reduction in HDL plasma levels.1–5 Usually, an inverse
correlation exists between triglycerides and HDLThe association of lipid risk factors with peripheral
plasma levels as a consequence of the metabolism ofvascular disease (PVD) has not been studied as ex-
triglyceride-rich lipoproteins.16 We did not find anytensively as has their association with coronary artery
difference in triglycerides between patients and con-disease.1,3 Elevated total cholesterol and LDL-cho-
trols.lesterol have not been consistently associated with
Lp(a) promotes cholesterol accumulation in thePVD.13,14 By contrast, decreased total cholesterol and
arterial wall and is antifibrinolytic because it com-LDL-cholesterol has been observed in subjects with
petes with plasminogen for binding sites on cells andcomplicated PVD.3 It has also been reported that el-
fibrin.8 Recent data have suggested a strongevated cholesterol predated symptomatic PVD, but
relationship between Lp(a) and PVD in both men andwith the progression of the disease there was a fall in
women.3,6,7,17,18 We have found a significant increase inthe cholesterol level.15 In contrast, Chen et al.7 observed
Lp(a) serum levels in patients with atheroscleroticsignificantly higher levels of serum cholesterol, tri-
glycerides and LDL. We did not observe any difference occlusive disease of the lower extremities compared
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